|
Abstract:
Targeted alpha therapy (TAT) offers the potential to inhibit the growth of micrometastases by selectively killing isolated and preangiogenic clusters of cancer cells. The alpha emitting radioisotopes Tb-149 and Bi-213 were produced by accelerator and generator, respectively, and chelated to cancer affined monoclonal antibody, peptide or protein to form the alpha-immunoconjugates (AIC) and alpha-plasminogen activation inhibitor type-2 (API) against melanoma, leukaemia, breast, prostate and colorectal cancers. These conjugates are tested for stability, specificity and cytotoxicity, and found to be highly specific and cytotoxic in vitro. Subcutaneous inoculation of one million melanoma or breast cancer cells into the flanks or mammary pads, respectively, of nude mice causes tumours to grow in all mice. Melanoma and breast cancer tumour growth is obtained for untreated controls, nonspecific and specific TAT, for 2 days post-inoculation subcutaneous injection models. Only for TAT mice is complete inhibition of melanoma growth found.
| Limitations: |
 APPROVED FOR PUBLIC RELEASE |
| Description: |
Annual rept. 15 Jul 1999-14 Jul 2000 |
| Pages: |
75 |
| Report Date: |
AUG 2000 |
| Contract Number: |
DAMD179919383 |
| Report Number: |
B232262 |
|
|
|
|
|
Keywords relating to this report:
Email This Abstract
